Insulet Q2 FY25: where the revenue came from and where it went
The whole income statement of Insulet for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Aug 7, 2025
Revenue$0.65B
+33% year over year
Gross profit$0.45B
70% margin
Operating profit$0.12B
19% margin
Net profit$0.02B
3% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 0.65 | 100% | +33% |
| U.S.Omnipod | 0.45 | 70% | +29% |
| International omnipod | 0.19 | 29% | +45% |
| Drug delivery | 0.01 | 1% | +26% |
| Cost of revenue | −0.20 | 30% | |
| Gross profit | 0.45 | 70% margin | +2pp |
| R&D | −0.07 | 11% | +0pp |
| SG&A | −0.26 | 40% | −6pp |
| Operating profit | 0.12 | 19% margin | +7pp |
| Interest & other costs | −0.09 | ||
| Tax | −0.01 | ||
| Net profit | 0.02 | 3% margin | −35pp |
129 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest